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OBJECTIVE—To investigate the effects of acute hypoglycemia
on working memory and brain function in patients with type 1
diabetes.
RESEARCH DESIGN AND METHODS—Using blood oxygen
level–dependent (BOLD) functional magnetic resonance imaging
during euglycemic (5.0 mmol/L) and hypoglycemic (2.8 mmol/L)
hyperinsulinemic clamps, we compared brain activation response
to a working-memory task (WMT) in type 1 diabetic subjects
(n = 16) with that in age-matched nondiabetic control subjects
(n = 16). Behavioral performance was assessed by percent cor-
rect responses.
RESULTS—During euglycemia, the WMT activated the bilateral
frontal and parietal cortices, insula, thalamus, and cerebellum in
both groups. During hypoglycemia, activation decreased in both
groups but remained 80% larger in type 1 diabetic versus control
subjects (P , 0.05). In type 1 diabetic subjects, higher HbA1c was
associated with lower activation in the right parahippocampal
gyrus and amygdala (R
2 = 0.45, P , 0.002). Deactivation of the
default-mode network (DMN) also was seen in both groups dur-
ing euglycemia. However, during hypoglycemia, type 1 diabetic
patients deactivated the DMN 70% less than control subjects (P ,
0.05). Behavioral performance did not differ between glycemic
conditions or groups.
CONCLUSIONS—BOLD activation was increased and deactiva-
tion was decreased in type 1 diabetic versus control subjects
during hypoglycemia. This higher level of brain activation required
by type 1 diabetic subjects to attain the same level of cognitive per-
formance as control subjects suggests reduced cerebral efﬁciency
in type 1 diabetes. Diabetes 60:3256–3264, 2011
A
cute episodes of hypoglycemia are a rate-limiting
adverse effect in the treatment of type 1 diabetes.
When severe, they can lead to seizures and coma
(1). Even mild to moderate hypoglycemia is
known to impair cognitive functions, such as working
memory (2,3). Working memory is used to actively main-
tain and manipulate information over a brief period of
time and to allocate attentional resources among competing
subtasks (4,5). Traditionally, working-memory performance
is thought to depend primarily on a network of brain regions,
including portions of the frontal and parietal lobes, thala-
mus, precuneus, cerebellum, and insula (6,7).
Using blood oxygen level–dependent (BOLD) functional
magnetic resonance imaging (fMRI), we evaluated how
diabetes impacts these neural processes under euglyce-
mic and hypoglycemic conditions when subjects were
presented with a working-memory task (WMT). Diabetes
is known to negatively affect working memory (8). This
task evaluates functional effects that might reﬂect changes
in brain structure and/or presage decreases in cogni-
tive performance. A better understanding of the brain’s
metabolic and physiological mechanisms underlying
the cognitive functions implicated in working memory
could lead to improved treatment strategies to help main-
tain cortical function in patients with diabetes during hy-
poglycemia (9).
BOLD fMRI is a well-established method for examining
regional brain activation in response to physiological, phar-
macological, sensory, or cognitive tasks (10). Studies that
have examined brain activation in response to sensory
stimulation or cognitive challenges using BOLD fMRI during
hypoglycemic conditions in nondiabetic subjects (11–13)
have shown that hypoglycemia reduces regional brain BOLD
activation. This reduction in BOLD response during hypo-
glycemia has been attributed to low glucose levels causing
decreases in neuronal activity, glucose oxidative metabo-
lism, cerebral blood ﬂow, neurovascular coupling, and/or
neuronal recruitment (12).
Whether cognitive function in patients with type 1 di-
abetes is affected by hypoglycemia in the same manner as
in nondiabetic individuals remains unclear because few
studies using functional neural imaging have directly com-
pared diabetic and nondiabetic subjects during the perfor-
mance of cognitive tasks (14,15). If brain glucose transport
or metabolism are altered in type 1 diabetes, as has been
suggested in recent studies by our group (16) and others
(17), then one would expect that the BOLD activation re-
sponse during hypoglycemia may differ between diabetic
patients compared with nondiabetic control subjects. On
the basis of these ﬁndings, we hypothesized that 1) patients
with type 1 diabetes would have greater BOLD activation
during the performance of a WMT during hypoglycemia
when compared with nondiabetic control subjects, 2)c o g -
nitive performance would deteriorate during hypoglycemia
in both groups, and 3) among type 1 diabetic patients, better
glycemic control (lower HbA1c) would correlate with BOLD
activation responses to the WMT during hypoglycemia. We
also conducted exploratory analyses to examine deactivation
patterns in the default-mode network (DMN), the regions
of the brain that are more active during rest (18), because
of other research by our group examining the effects of
diabetes on deactivation patterns during cognitive tasks
and previous research suggesting that DMN function may
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ORIGINAL ARTICLEbe altered in diseases that affect cognition, such as
Alzheimer’s disease (19).
RESEARCH DESIGN AND METHODS
The study sample consisted of 16 patients with type 1 diabetes and 16 healthy
control subjects from an ongoing study of brain function during hypoglycemia
in type 1 diabetes. Data from ﬁve type 1 diabetic and ﬁve control subjects were
included in a previous publication (20). Demographic and clinical character-
istics of the subjects are presented in Table 1. The patients’ number of self-
reported hypoglycemic episodes (plasma glucose ,3.9 mmol/L with concomitant
symptoms) in the month preceding the initial visit averaged eight episodes
(range 2–28). Patients with autonomic neuropathy (assessed by standard cri-
teria ) (21), painful peripheral neuropathy, urinary albumin levels .300 mg/day,
or proliferative retinopathy by review of medical records, physical exam, or
self-report were excluded from the study. Other exclusion criteria were
a history of psychosis or schizophrenia; cocaine, heroin, or alcohol de-
pendence; and any contraindications to MRI, such as metallic implants,
pregnancy, or claustrophobia.
Following approval from the institutional review boards of both the Joslin
Diabetes Center (where patients were recruited) and the McLean Hospital
(where the MRI was performed), patients provided the following information
during screening: self-report of their lifetime experience of severe hypogly-
cemic events leading to unconsciousness (22); psychiatric history; handed-
ness; medical history; and current medications.
Of 18 control participants who were eligible for the study, 2 were excluded
from analysis because of excessive head motion during the fMRI by applying
exclusion criteria of translations in excess of 3 mm in x, y,o rz directions or
rotations in excess of 3° around the x, y,o rz axes. No diabetic subjects were
excluded for head motion.
Experimental protocol. The experimental protocol is described elsewhere
(20) and brieﬂy reviewed below. On the day before the study, patients with type
1 diabetes had a continuous glucose monitor (CGM System Gold; Medtronic,
Northridge, CA) inserted. If the continuous glucose monitor showed glucose
,3.3 mmol/L, the study was postponed to a later date. The experiment used the
insulin clamp technique with four successive time periods corresponding to
different plasma glucose levels: baseline (30 min); euglycemic clamp (40 min,
target glucose 5.0 mmol/L); declining glycemia (40 min, plasma glucose reduced
from 5.0 to 2.8 mmol/L); and hypoglycemic clamp (30 min, target glucose
2.8 mmol/L). Anatomical MRI was performed during baseline, and fMRI was
performed during the euglycemic and hypoglycemic periods while the WMT
was administered (Fig. 1).
Insulin clamp technique. An intravenous catheter was inserted into an
antecubital vein for the administration of insulin and glucose, and a second
catheter was inserted into a distal forearm or hand vein for the withdrawal of
blood samples. A heated gel pack was used to warm the hand to arterialize the
venousblood.Afterthebaselineperiod,regularhumaninsulinwasinfusedat12
pmol/kg per min for 110 min. The plasma glucose levels were maintained at the
desired level by infusion of 20% dextrose using a negative-feedback algorithm,
as previously described (23–25). After the euglycemic clamp period (40 min),
the glucose infusion rate was reduced to allow the plasma glucose level to
decline by 2.2 mmol/L (from 5.0 to 2.8 mmol/L) over the next 40 min, followed
by the 30-min hypoglycemic clamp period. During the entire clamp protocol,
glucose levels were measured every 5 min, and counterregulatory hor-
mones (epinephrine, cortisol, growth hormone, and glucagon) were mea-
sured every 10 min. At the end of the protocol, the insulin infusion was
discontinued, the glucose infusion was increased to restore euglycemia,
and the subjects were given a meal and discharged.
Hormone and substrate assays. Plasma glucose was measured using the
glucose oxidase method. Serum insulin and growth hormone and plasma
epinephrine were measured by enzyme-linked immunosorbent assay. Plasma
glucagon and cortisol were measured by radioimmunoassay.
WMT. The task stimuli were administered using Presentation software (Neu-
robehavioral Systems, Albany, CA). The images were projected on a backlit
screen that was visualized from within the magnet bore by a mirror mounted
on the head coil. Response times and errors were collected using a magnetic
resonance–compatible hand-held four-button ﬁberoptic response pad (FORP;
Current Designs, Philadelphia, PA) connected to the PC by an optical cable
interface. The stimulus presentation was synchronized with the fMRI acqui-
sition sequence at the beginning of each trial by the interface that responded
to scanner-generated trigger signals. The WMT was administered 15–20 min
after the beginning of the euglycemic period and again at 15–20 min after the
TABLE 1
Demographic and clinical characteristics of study subjects
Type 1 diabetic
subjects Control subjects
n 16 16
Age (years) 33.8 6 9.9 (19–50) 31.3 6 10.0 (19–50)
Sex
(men/women) 8/8 13/3
Diabetes duration
(years) 16.7 6 4.9 (7.9–26.7) —
BMI (kg/m
2) 24.8 6 2.9 (20.5–30.7) 25.1 6 3.1 (20.2–31.1)
HbA1c (%) 7.4 6 1.1 (5.7–9.7) 5.2 6 0.3 (4.4–5.5)
Fasting plasma
glucose
(mmol/L) 6.0 6 1.4 (4.1–8.7) 5.0 6 0.3 (4.4–5.6)
Education (years) 16.3 6 1.9 (13–20) 16.8 6 2.7 (12–21)
Data are means 6 SD (range).
FIG. 1. Study protocol. Time line of structural and functional scans, WMTs, and periods of euglycemia (nominal 5.0 mmol/L), glucose descent, and
hypoglycemia (nominal 2.8 mmol/L).
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tests before the study to achieve familiarity with the test procedure, and we
used randomly assigned counterbalanced forms of the test during euglycemia
and hypoglycemia to minimize learning.
During the WMT, adapted from Rypma et al. (26), participants viewed
a string of six digits for 1,200 ms followed by a 2,000-ms unﬁlled retention
interval (blank screen). Then, one digit was displayed on the computer monitor
for 1,500 ms, and the subject had 1,300 ms to decide whether the digit was
a member of the previously seen string. Using the same timing parameters,
a matched control task was used in which subjects viewed six percent symbols
(%) on the screen, followed by the unﬁlled retention interval, followed by
a right- or a left-pointing arrow. The participants were asked to press the re-
sponse key corresponding to the direction of the arrow. In the rest task, par-
ticipants ﬁxated on a plus (+) sign for 30 s. Each of these three tasks (WMT,
matched control, and rest) was presented four times in a block design for
a total of 6 min of testing. There were 5 memory-scanning trials per block for
a total of 20 memory-scanning trials.
MRI acquisitionmethods.All magnetic resonance images were acquired with
a 3.0 Tesla Siemens Trio scanner (Siemens, Erlangen, Germany), using a cir-
cularly polarized birdcage radiofrequency head coil tuned to the proton fre-
quency. Global ﬁeld uniformity was adjusted at the beginning of each scanning
session using Siemens’ automated shimming routines. A three-dimensional,
T1-weighted anatomical image was acquired using a magnetization-prepared,
rapid-acquisition gradient echo sequence (TR/TE = 2,100/2.74 ms; spatial reso-
lution = 1 3 1 3 1.3 mm
3; matrix size = 256 3 256 3 128) and used for functional
image registration. BOLD fMRI images covering the whole brain were acquired
in the axial plane using an echo planar imaging (EPI) sequence (TR/TE = 3,000/
30 ms; 26 slices acquired in interleaved scanning order; slice thickness = 5 mm;
ﬁeld of view = 200 3 200 mm
2; matrix size = 64 3 64), with an in-plane
resolution of 3.125 3 3.125 mm
2. One multislice EPI volume covering the
whole brain was acquired every 3 s for a total of 120 volumes for the 6-min
fMRI run.
Image processing. Image processing and analyses were performed using
the FSL software package (Analysis Group, FMRIB, Oxford, U.K.) running on a
Mac-Pro Quad-Core Intel-Xeon computer (Apple,Cupertino,CA). Allbrain images
were registered to the standard MNI-152 brain (Montreal Neurologic Institute)
toallowmultisubjectanalysesinstandardizedspaceandidentiﬁcationofall
regions of interest. The ﬁrst two EPI volumes of each functional run were
discarded to allow for T1 equilibration. Prestatistical processing of EPI time
series consisted of motion correction, slice scan-time correction, nonbrain
removal, spatial smoothing with a 6-mm full-width at half-maximum three-
dimensional Gaussian ﬁlter, linear trend removal, and a temporal high-pass
ﬁlter with a cutoff of 120 s. Functional data were overlaid on the MNI-152 brain.
Data analyses. Regional brain activations and deactivations in response to
the WMT were examined by performing a ﬁrst-level general linear model
(GLM) multiple regression analysis for each subject and glycemic condition.
Model predictors for BOLD signal time courses were the boxcar time
courses for each task stimulus paradigm convolved with a g function to
account for hemodynamic response. Predictors for the temporal derivatives
of the task paradigm were added to the design matrix to improve the ﬁt
t ot h ed a t ab ya l l o w i n gf o rp o t e n t i a lm i s s p e c i ﬁcation of the hemodynamic
delay (27). The model for the baseline rest condition predictor was a con-
stant function.
To compare activation and deactivation patterns between groups and
conditions, higher-level multisubject mixed-effects GLM analyses compared
multipleregressioncorrelationcoefﬁcientsassociatedwitheachmodelpredictor
for each brain voxel for each subject under each condition. Activations were
computed by contrasting the WMT task to its control task. Deactivations were
computed by contrasting the WMT task to the rest period. These higher-level
analyses were performed using FSL’s local analysis of mixed effects stage 1.
Resulting Z score (i.e., Gaussianized T/F) statistic images were thresholded
using clusters determined by Z . 2.3 and a corrected cluster signiﬁcance
threshold of P = 0.05 (28). These statistical parametric maps yield the clusters
of adjacent brain voxels of regional activation or deactivation from which we
FIG. 2. Plasma levels of counterregulatory hormones (error bars 6 SE) during the baseline and euglycemic periods and at the end of the hypo-
glycemic period in control subjects and patients with type 1 diabetes (T1DM). EU, euglycemia; HYPO, hypoglycemia. P values for statistically
signiﬁcant comparisons: *P < 0.05 vs. baseline; †P < 0.05 vs. euglycemia; ‡P < 0.01 vs. baseline; §P < 0.01 vs. euglycemia; cP < 0.05 vs. control
subjects; ¶P < 0.001 vs. control subjects.
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tistical signiﬁcance threshold (P , 0.05).
To investigate the variation of the regional percent BOLD signal change,
we applied a region-of-interest (ROI) analysis in the superior parietal lobule
(SPL) region, which had signiﬁcant activation differences during hypogly-
cemia.TodeﬁnetheROI,wecreatedabinarymaskoftheSPLregionprovided
by the probabilistic Harvard-Oxford Cortical Structural Atlas (29) thresh-
olded at the 50% probability level. The ROI analysis was performed using
FSL’s FEATQUERY tool to extract the average time courses of parameter
estimates of the percent BOLD signal change from all voxels contained in the
SPL mask.
To investigate the association of WMT activation and deactivation to gly-
cemic control in type 1 diabetes, we performed the mixed-effects GLM group
analyses while including HbA1c values as a covariate in the design matrix. To
compute the regional coefﬁcients of correlation of activation to HbA1c,t h e
average percent BOLD activation values were extracted from the regions of
signiﬁcant correlation in type 1 diabetes during hypoglycemia using the
FEATQUERY tool.
Standard statistical tests, including t tests for paired and unpaired data as
appropriate, and ANOVA were used to compare glucose and counter-
regulatory hormone levels between diabetic and nondiabetic subjects during
euglycemia and hypoglycemia. All data are presented as means 6 SEM, unless
FIG. 3. BOLD activation during the WMT in control and type 1 diabetic (T1DM) subjects during euglycemia and hypoglycemia. Statistical parametric
maps of regions of greatest activation during WMTs vs. control tasks for each subject group and glycemic condition. Functional activations (red-to-
yellow color scale) are overlaid on the MNI-152 standard brain anatomy (gray scale). The threshold for activation was P < 0.05 after correction for
multiple comparisons using the cluster-based threshold method(see RESEARCH DESIGN AND METHODS). During hypoglycemia, type 1 diabetic subjects exhibit
greater activation than control subjects during the WMT. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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level of 0.05.
RESULTS
Plasma glucose and counterregulatory hormones.
Average plasma glucose levels during the euglycemic period
for nondiabetic control and type 1 diabetic subjects were
5.0 6 0.4 mmol/L and 5.0 6 0.6 mmol/L, respectively. During
the hypoglycemic period, average glucose levels for the
two groups were 2.8 6 0.2 mmol/L and 2.7 6 0.1 mmol/L,
respectively. There was no signiﬁcant difference between
groups and no signiﬁcant interaction between the glycemic
condition and group. Mean counterregulatory hormone lev-
els during baseline and euglycemia and peak levels attained
during hypoglycemia are shown in Fig. 2. Glucagon and epi-
nephrine secretion were lower in the type 1 diabetic patients
during hypoglycemia compared with control subjects.
Cognitive performance. Type 1 diabetic and control sub-
jects did not differ in accuracy or reaction time during
the WMT at either euglycemia or hypoglycemia. During
euglycemia, control subjects achieved 85 6 2% correct,
with a reaction time of 1,133 6 54 ms, whereas type 1
diabetic patients had 85 6 4% correct, with a reaction time
of 1,200 6 57 ms. At hypoglycemia, control subjects had
84 6 5% correct, with a reaction time of 1,122 6 57 ms,
whereas type 1 diabetic patients had 85 6 4% correct, with
a reaction time of 1,204 6 58 ms. There were no signiﬁcant
within-subject differences for either group when compar-
ing the performance between glycemic conditions and no
interaction between group and condition.
Functional imaging. Brain activations in response to the
WMT for each subject group during each glycemic condi-
tion are shown in Fig. 3. The regions of greater BOLD ac-
tivation for the WMT relative to the control task (P , 0.05,
corrected for multiple comparisons using the cluster-based
threshold method) (28) are indicated in a red-to-yellow
color scale overlaid on the gray scale standard MNI-152 T1-
weighted anatomical brain atlas. For both subject groups
during both glycemic conditions, the WMT activated brain
regions located in bilateral medial superior frontal gyrus,
left precentral gyrus, bilateral SPL, bilateral middle frontal
gyrus, bilateral anterior cingulate cortex, bilateral insula,
left supramarginal gyrus, bilateral thalamus, bilateral in-
ferior occipital cortex, and bilateral cerebellum.
During euglycemia, the overall extent of activation was
similar in the diabetic patient and control groups, with ac-
tivated brain volumes of 613 and 498 cm
3,r e s p e c t i v e l y .
During hypoglycemia, the extent of regional BOLD acti-
vation decreased relative to euglycemia in both subject
groups; however, it decreased less in patients with diabe-
tes than in control subjects (P , 0.05). The regional pat-
terns of activation also differed between groups. In type 1
diabetes, activation decreased mostly in the insula,
FIG. 4. Percent BOLD activation by ROI analysis during the WMT during euglycemia (left) and hypoglycemia (right). Upper:L o c a t i o no ft h e
superior parietal lobule (SPL, association cortex including Brodmann areas 7 and 40) region used for ROI analysis is indicated at the in-
tersection of the crosshairs on the activation maps for each subject group overlaid on the MNI-152 standard brain. Lower:P l o t so ft h et i m e
courses of change in percent BOLD activation in the SPL ROI during the fMRI WMT. Percent change was measured relative to BOLD activation
during the control task and averaged over all pixels in the ROI and all subjects within each subject group. The colored strip above the hori-
zontal time axis shows the time sequence of task conditions. CONT, control task; REST, resting state task. (A high-quality digital represen-
tation of this ﬁgure is available in the online issue.)
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in the cerebellum. Regions with higher activation in type 1
diabetes during hypoglycemia include the bilateral SPL, bi-
lateral posterior supramarginal gyrus, bilateral anterior and
posterior cingulate gyrus, left inferior frontal gyrus and
posterior middle temporal gyrus, right hippocampus, and the
cerebellum. Thus, during hypoglycemia, activation volumes
were 80% larger in type 1 diabetic versus control subjects,
with activation volumes of 431 and 239 cm
3, respectively
(P , 0.05). The extended activation volume in type 1 diabetic
relative to control subjects during hypoglycemia was mainly
a result of maintenance of a higher percent BOLD activation
during the WMT, as illustrated in Fig. 4, which compares
the time courses of the percent BOLD signal estimates
averaged over the SPL region for each subject group under
each glycemic condition.
Regional brain deactivations in response to the WMT for
each subject group during each glycemic condition are
shown in Fig. 5. Regions of lesser BOLD activation (or more
deactivation) for WMT relative to the resting task (P , 0.05,
corrected for multiple comparisons using the cluster-based
threshold method) (28) are indicated in a dark blue–to–light
blue color scale overlaid on the standard MNI-152 T1-
weighted anatomical brain atlas in gray scale, along with
activations in red to yellow. During euglycemia, WMT
deactivated brain regions located in bilateral medial fron-
tal cortex, posterior cingulate cortex, and superior lateral
occipital cortex for both groups. The extent of deactivation
was similar in the type 1 diabetic and control groups, with
only a 10% difference between groups. Overall, deactivated
brain volumes were 45 and 41 cm
3, respectively. During hy-
poglycemia, the extent of regional BOLD deactivation
decreased relative to euglycemia in both subject groups;
however, it decreased more for patients with type 1 diabetes
(P , 0.05) (i.e., they were unable to signiﬁcantly deactivate
these regions).
The regional patterns of decreased deactivation also
differed between groups (Fig. 5). For patients with type 1
diabetes, deactivation decreased mostly in the medial
frontal and posterior cingulate cortices, whereas for con-
trol subjects, deactivation decreased mostly in the poste-
rior cingulate cortex. Control subjects also had small
deactivation volumes in the cerebellum (right crus II) during
hypoglycemia only. Thus, during hypoglycemia, the extent of
deactivation was almost 70% smaller in type 1 diabetic rel-
ative to control subjects, with deactivation volumes of 5 cm
3
located in the superior lateral occipital cortex for patients
and 17 cm
3 located mainly in the medial frontal and superior
lateral occipital cortices for control subjects (P , 0.05).
Finally, we examined the relationship of HbA1c levels
with activation patterns in type 1 diabetes by entering HbA1c
as a covariate into the GLM. We found that lower HbA1c
levels were associated with higher activation in the right
parahippocampal gyrus and the amygdala (Fig. 6) during
hypoglycemia. We also found that HbA1c levels were not
associated with deactivation.
DISCUSSION
This study demonstrates that patients with type 1 diabetes
show a different pattern of brain activation in response to
a WMT than do nondiabetic control subjects during hy-
poglycemia. Speciﬁcally, we found that for patients with
type 1 diabetes during hypoglycemia, WMT-related activa-
tion responses were increased in several cortical regions,
including the parietal and frontal cortices, hippocampus,
and cerebellum. Task-induced deactivations, typically ob-
served in the DMN during cognitive effort, were signiﬁcantly
suppressed during hypoglycemia in bilateral medial-frontal
and posterior cingulate cortices for type 1 diabetic patients
compared with control subjects. Activation and deactivation
patterns were similar across groups during euglycemia. Be-
havioral performance on the WMT was similar across groups
and conditions. Finally, HbA1c was inversely correlated with
WMT activation during hypoglycemia in the right para-
hippocampal gyrus and amygdala, two areas that have been
reported to activate in memory-disordered populations as
a form of compensatory recruitment (30–32).
The regional BOLD activations we observed in response
to the WMT were compatible with those found in other
fMRI studies of similar WMTs (5,26,33–35). Although the
main regions that help govern working memory are the
dorsolateral and medial prefrontal cortices and anterior
cingulate cortex, other regions, such as the parietal lobe
(36) and cerebellum (37), are known to play supplemen-
tary roles. These regions were activated more in type 1
diabetic patients than in control subjects during hypogly-
cemia, suggesting that supplementary brain regions may
have been recruited to help preserve cognitive perfor-
mance. The failure to suppress activation in the DMN also
is consistent with an interpretation that type 1 diabetic
patients need to recruit more brain resources for cognitive
preservation (11). Similar patterns of increased activation
and decreased deactivation have been observed with mild
cognitive impairment (30) and in older individuals at risk
for Alzheimer’s disease (38), suggesting, in these cases,
a compensatory response to accumulating pathology.
Cognitive performance was not altered by hypoglycemia
in either subject group. Although some studies have shown
similar results for less challenging WMTs (39), others have
FIG. 5. BOLD activation and deactivation during the WMT in type 1
diabetic (T1DM) and control subjects during euglycemia and hypogly-
cemia. Statistical parametric maps of regions of greatest activation
during WMTs vs. control tasks (functional activations in the red-to-
yellow color scale) and regions of decreased activation during the
WMTs vs. resting tasks (functional deactivations in the blue color
scale) are overlaid on the MNI-152 standard brain anatomy (gray
scale). The threshold for activations and deactivations was P < 0.05
after correction for multiple comparisons using the cluster-based
threshold method (see RESEARCH DESIGN AND METHODS). During hypoglyce-
mia, patients with type 1 diabetes exhibit less deactivation than control
subjects. (A high-quality digital representation of this ﬁgure is avail-
able in the online issue.)
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challenging WMTs involving reasoning (2). Of importance,
a number of studies have used the same Sternberg WMT
used here to evaluate differences in brain activation pat-
terns across different populations (40,41). In our study,
different brain activation patterns, despite similar cognitive
performance across groups, suggest unique strategies of
brain recruitment used across groups to augment perfor-
mance during the glycemic challenge.
Our results showing hyperactivation of brain regions
in type 1 diabetic patients with low HbA1c and hypo-
activation in patients with higher HbA1c could reﬂect
upregulation of glucose transport in the brain, as seen in
patients with good glycemic control (42,43). Type 1 dia-
betic patients may engage more brain regions to maintain
the same performance to compensate for cerebral in-
efﬁciency attributed to reduced brain resources (44).
These results also are consistent with the patterns ob-
served in many physiologic systems in which a period of
compensatory hyperfunction precedes functional decline
and ultimate organ-system failure.
In an earlier report from our group, we demonstrated that
type 1 diabetic patients showed reduced gray-matter density
in the parahippocampal gyrus associated with higher HbA1c
(45). One possible explanation may be that gray-matter loss
in this temporal region prevents its participation in the
brain’s response to moderate acute hypoglycemia. Wessels
et al. (46) also observed abnormal brain activity pat-
terns in patients with diabetes retinopathy, which is
more likely to be associated with elevated HbA1c lev-
els. However, our studies differed in both design and
data analytic methodology, making a direct comparison
difﬁcult.
The differences in the hypoglycemic BOLD response
between patients and control subjects found in this study
may be attributed to a variety of mechanisms, including
preservation of global brain glucose uptake in diabetes as
a result of adaptation to hypoglycemia (12,47), differences
in neurovascular coupling, resting cerebral blood ﬂow,
neuronal activity linked to oxidative metabolism, increased
brain glycogen stores (48), or a tendency to use nonglucose
substrates to support higher neuronal activity (49). In ad-
dition, changes in brain glucose transport or metabolism,
resulting in increased brain glucose levels, might occur as
a result of recurrent hypoglycemia. We reported such
a ﬁnding along with accompanying increases in glutamate
FIG. 6. Regions of BOLD activation inversely correlated with HbA1c in patients with type 1 diabetes. Upper: Statistical parametric map of the
correlation of WMT activation with HbA1c in patients with type 1 diabetes during hypoglycemia (P < 0.05). Sagittal, coronal, and axial slices (from
left to right) showing activation correlation in a red-to-yellow scale overlaid on the MNI-152 standard brain anatomy (gray scale). These HbA1c-
correlated activation clusters were identiﬁed in the right parahippocampal gyrus and amygdala using the Harvard-Oxford Cortical Structural Atlas.
Lower: Plots of regional percent BOLD activation vs. HbA1c for patients with type 1 diabetes during euglycemia (left) and hypoglycemia (right).
Filled circles with error bars: average percent BOLD activation for each patient 6 SD within the region of activation. The line is the linear regression
best ﬁt of the data with its correlation coefﬁcient R
2. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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tive function (16). It may follow that abnormal glutamate
metabolism contributed to altered neurovascular coupling in
patients in our study. Although these adaptive mechanisms
in type 1 diabetes may in the short-term allow compensation
for altered brain activity patterns during a hypoglycemic
challenge, they may presage long-term maladaptive or ad-
verse consequences.
Although our study demonstrates greater activation
during hypoglycemia in type 1 diabetes along with reduced
deactivation of the DMN, the small sample size may limit
the implications of our results. However, the regional BOLD
activations we observed in response to the WMT were
compatible with regional activations found in other fMRI
studies of similar WMTs (5,26,33–35). The reductions in
BOLD response observed during hypoglycemia were also
compatible with other reports showing reduced brain BOLD
activation in primary or association cortex in response to
sensory, motor, or cognitive tasks in nondiabetic subjects
(11,12,14,47). Also, this study was unable to resolve whether
the alterations in brain activation were secondary to
chronic hyperglycemia or recurrent hypoglycemia. Future
studies can help resolve this issue.
In summary, patients with type 1 diabetes activate more
brain regions than control subjects during hypoglycemia
by maintaining activity from euglycemia to hypoglycemia
in task-relevant regions and by failing to suppress activa-
tion in the DMN. This suggests that type 1 diabetic patients
may need to recruit more brain resources to preserve
cognitive performance. The pattern of hyperactivation of
both the DMN and task-relevant regions is consistent with
ﬁndings in disease states with impaired cognition, such as
mild cognitive impairment and Alzheimer’s disease (38).
There has been persistent concern about the consequences
of recurrent hypoglycemia on brain structure and cogni-
tive function. There are minimal long-term effects of re-
current hypoglycemia on cognition into middle age (50),
but it is not clear whether this resiliency will last throughout
the aging process. Future research should evaluate our
ﬁndings as an early manifestation and warning of future
clinically relevant cognitive decline. This research may
guide the development of treatment regimens to enhance
symptom recognition or to stabilize the neurochemical
response to hypoglycemia to reduce the impact of gluco-
deprivation on cognitive function.
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